News Search Results
Nov 28, 2025, 11:59 ET Angel Yeasts 8.500-Tonnen-Anlage für Spezialhefen und neue Pilotplattform für Braumikroben gehen online
(SH600298), ein weltweit führender Anbieter von Hefe- und Fermentationslösungen, hat mit der Testproduktion seines neuen Spezialhefeprojekts im Baiyang Biotechnology Park in der Yichang Hightech Zone begonnen. Die Anlage hat am 31. August mit der Materialzufuhr begonnen und wird nach vollständiger Inbetriebnahme
More news about: Angel Yeast
Nov 28, 2025, 10:30 ET Medical Membranes Market worth $6.66 billion by 2030 - Exclusive Report by MarketsandMarkets™
membranes market. The necessity for ultra-pure water, sterile solutions, and drugs without any impurities in the processes of drug development, biotechnology, and lab testing is driving the growth in pharmaceutical filtration application. Microfiltration, ultrafiltration, and nanofiltration are the key
More news about: MarketsandMarkets
Nov 28, 2025, 08:19 ET HZICC：Unlocked potential: why global innovators choose Hangzhou
multiple districts in Hangzhou. They weren't just offering incentives; they were offering partnerships." In early 2023, he established Hangzhou Haofan Biotechnology Co.,Ltd in Lin'an district, attracted by the area's talent policies and scenic research environment. "The local government supported us at every
More news about: HZICC
Nov 28, 2025, 07:57 ET Angel Yeast's 8,500-Ton Specialty Yeast Facility and New Brewing Microbial Pilot Platform Come Online
Yeast (SH600298), a global leader in yeast and fermentation solutions, has begun trial production at its new specialty yeast project in the Baiyang Biotechnology Park, Yichang High‑tech Zone. The facility commenced material feeding on August 31 and, once fully ramped, will reach an annual capacity of 8,500
More news about: Angel Yeast
Nov 28, 2025, 05:46 ET CRO Industry to Hit USD 127.77 Billion by 2030 Driven by Advanced Clinical Trial Models and Led by North America, Says Mordor Intelligence
region.Major Trends Shaping Market DynamicsRising Outsourcing of Clinical Research Activities - Pharmaceutical and biotechnology companies are increasingly outsourcing preclinical and clinical development functions to CROs to focus on core innovation, reduce operational risk,
More news about: Mordor Intelligence Private Limited
Nov 28, 2025, 00:00 ET Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
/PRNewswire/ -- Imugene Ltd (ASX:IMU), a clinical-stage immuno-oncology company, and JW Therapeutics (Shanghai) Co., LTD (HKEX:2126), a leading biotechnology company focused on cell-based immunotherapies, today announced a co-development collaboration to evaluate the combination of Imugene's oncolytic
More news about: Imugene Ltd
Nov 27, 2025, 21:01 ET Aphranel debuta en SAAM 2025, destacando el CaHA original y la técnica de inyección MagiCConcept
28 de noviembre de 2025 /PRNewswire/ -- Aphranel, una marca estética original con sede en China de SHANGHAI MOYANG BIOTECHNOLOGY, participó en el 4º Congreso Científico de Medicina Estética de Arabia Saudita (SAAM 2025) en Riad, presentando su relleno de hidroxiapatita de
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Nov 27, 2025, 10:47 ET Internet of Behaviors Market Surges to USD 14.3 Billion by 2033, Propelled by 26.5% CAGR - Verified Market Reports®
Management, Data Analytics and Insights), By End-User (Pharmaceutical Companies, Biotechnology Firms), By Functionality (Adverse Event Reporting, Signal Detection and Management), By Industry (Pharmaceutical Industry, Biotechnology Industry), By Geographic Scope And Forecast
More news about: Verified Market Reports
Nov 27, 2025, 10:10 ET Lateral Flow Assays Market to Soar to $17.44 Billion by 2033 Amid Robust 6.98% CAGR - Grand View Research
2021 - 2033)Hospitals & ClinicsDiagnostic LaboratoriesHome CarePharmaceutical & Biotechnology CompaniesOthersLateral Flow Assays Market - Regional Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
More news about: Grand View Research, Inc
Nov 27, 2025, 09:00 ET Strategic Partnership | Sanyou Bio and Korea's FatiAbGen Join Forces to Expand the Global Biopharma Market
operation or under development.The company has established sound cooperative relationships with over 2,000 pharmaceutical companies and biotechnology firms globally, has empowered more than 1,200 new drug R&D projects, and has completed over 50 cooperative R&D projects, more than 10 of
More news about: Sanyou Bio
Nov 27, 2025, 02:27 ET Aphranel präsentiert sich erstmals auf der SAAM 2025 und stellt das Original CaHA und die MagiCConcept-Injektionstechnik vor
27. November 2025 /PRNewswire/ -- Aphranel, eine in China ansässige ästhetische Originalmarke von SHANGHAI MOYANG BIOTECHNOLOGY, nahm am 4. wissenschaftlichen Kongress für ästhetische Medizin in Saudi-Arabien (SAAM 2025) in Riad teil, präsentierte seinen Calciumhydroxylapatit
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Nov 27, 2025, 02:27 ET Aphranel fait ses débuts au SAAM 2025, en mettant en avant le CaHA original et la technique d'injection MagiCConcept
27 novembre 2025 /PRNewswire/ -- Aphranel, une marque esthétique originale basée en Chine de SHANGHAI MOYANG BIOTECHNOLOGY, a participé au 4e Congrès scientifique de médecine esthétique d'Arabie Saoudite (SAAM 2025) à Riyadh, présentant son produit de comblement MagiCCrystal
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Nov 27, 2025, 00:34 ET IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma
SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel
More news about: IASO Bio
Nov 26, 2025, 19:25 ET Aphranel Debuts at SAAM 2025, Spotlighting Original CaHA and the MagiCConcept Injection Technique
Arabia, Nov. 27, 2025 /PRNewswire/ -- Aphranel, a China-based original aesthetic brand by SHANGHAI MOYANG BIOTECHNOLOGY, participated in the 4th Saudi Arabia Aesthetic Medicine Scientific Congress (SAAM 2025) in Riyadh, presenting its MagiCCrystal calcium hydroxyapatite
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Nov 26, 2025, 18:34 ET Elanco executive appointed as Neurizon's Board Observer
Neurizon Therapeutics Limited.About Neurizon Therapeutics LimitedNeurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment
More news about: Neurizon Therapeutics Limited
Nov 26, 2025, 18:15 ET Elanco executive appointed as Neurizon's Board Observer
Neurizon Therapeutics Limited.About Neurizon Therapeutics LimitedNeurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment
More news about: Neurizon Therapeutics Limited
Nov 26, 2025, 08:50 ET MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman
FRANCISCO, Nov. 26, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly 90% in a single day. The
More news about: Hagens Berman Sobol Shapiro LLP
Nov 26, 2025, 08:05 ET Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
Calif., Nov. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company
More news about: Rigel Pharmaceuticals, Inc.
Nov 26, 2025, 08:00 ET mAIbe and LenioBio announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies
and data-driven innovation in therapeutic antibody discovery by closing the lab-in-loop gap.About LenioBioLenioBio GmbH is a biotechnology company pioneering cell-free protein expression with its ALiCE® platform, enabling rapid discovery, development, and scalable production of proteins
More news about: LenioBio
Nov 26, 2025, 06:30 ET Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D.,
More news about: Immunic, Inc.
Nov 26, 2025, 06:10 ET Oral Care Market Poised to Grow to USD 86.8 Billion by 2035 with a Thriving CAGR of 6.75% | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Nov 26, 2025, 03:00 ET mAIbe and LenioBio announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies
and data-driven innovation in therapeutic antibody discovery by closing the lab-in-loop gap.About LenioBioLenioBio GmbH is a biotechnology company pioneering cell-free protein expression with its ALiCE® platform, enabling rapid discovery, development, and scalable production of proteins
More news about: LenioBio
Nov 26, 2025, 01:48 ET Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
as well as the novel biologic ZYMFENTRA® (infliximab-dyyb).Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Nov 26, 2025, 01:01 ET Plant Based Proteins and Novel Food Ingredients Market Set to Hit 106 billion Dollars by 2033 as Global Demand Accelerates says, Strategic Revenue Insights (SRI)
eat meals, protein enriched beverages, and nutrient dense supplements.Technological integration will intensify. Artificial intelligence, biotechnology, and advanced processing will enable companies to create more nutritious, flavorful, and accessible plant-based ingredients. Improvements in shelf
More news about: Strategic Revenue Insights
Nov 25, 2025, 20:16 ET Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America
Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered in Buenos Aires, Argentina, with decades of experience in biosimilar development and commercialization, for the commercialization
More news about: Prestige Biopharma Limited